Author + information
- Parikshit S. Sharmaa,b,
- Sampath Gundaa,b,
- Santosh Padalaa,b,
- Samir Pancholya,b and
- Kenneth Ellenbogena,b
Background: Patients with Atrial Fibrillation (AF) have a poorer quality of life (QoL) when compared to the general population. We assessed QoL outcomes between anti arrhythmic drug (AAD) therapy versus catheter ablation (CA) in a pooled sample of studies comparing the two strategies.
Methods: Using the keywords “Atrial Fibrillation Ablation”, “Anti-Arrhythmic drugs”, two independent authors (PS and SG), evaluated major databases including PubMed, Embase, Cochrane library and Google Scholar. Studies were included if they reported QoL outcomes using the SF36 questionnaire with the physical component survey score (PCS) and mental component survey score (MCS). Statistical analysis was performed using RevMan 5.0.
Results: A total of 310 studies were evaluated, of which 6 randomized and 3 observational studies met inclusion and exclusion criteria and were included. A total of 1652 patients, 793 in the CA arm and 859 in the AAD therapy arm were identified. There were no statistically significant differences in baseline PCS and MCS among patients undergoing AAD therapy vs CA for AF. After a follow up of 3 months, patients in CA arm had statistically significant improvement in PCS (MD: 10.55 (CI: 4.67-16.43), Z: 3.52, P= 0.0004) (Fig: 1A) and MCS (MD: 7.68 (0.73-14.64), Z: 2.17, P=0.03) (Fig: 1B) scores compared with patients in AAD therapy group.
Conclusions: Compared to AAD therapy, patient undergoing CA for AF, have a more significant improvement in average QoL scores as assessed in this pooled analysis.
Poster Hall, Hall C
Friday, March 17, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Atrial Fibrillation and VT: Unique Populations and Solutions
Abstract Category: 8. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias
Presentation Number: 1151-108
- 2017 American College of Cardiology Foundation